So you’re looking at something a little different today.
MedCity News unveiled a new look overnight – from a new logo to a new layout. But there are benefits beyond a prettier face. This platform will expand the reach of MedCity News’ reporting and delivers a more focused and distinct presentation of how we think about the changing world of healthcare innovation.
In January, MedCity News was acquired by the digital B2B publisher Breaking Media. This look is the signature design of Breaking Media’s sites. Getting on to this platform will enable MedCity News to share its articles across the Breaking Media family of publications: from sites that writing about government and defense, law, high finance and beyond.
That’s exciting to me, because it means the reporting we’re doing will reach an ever greater audience of stakeholders who can help support medical innovation.
We’ve also used the redesign of MedCityNews.com to re-arrange how we present our stories to you. MedCity’s mission has been to cover the business of healthcare innovation like an ecosystem: we break the silos because in today’s world we need to bring everyone together to tackle the big challenges and opportunities in medicine. So our main groupings are now focused on issues not sectors: patient engagement, healthcare convergence, investing and startups, and beyond.
You can still find your silos, though. Click the menu button in the top left corner and you’ll get an even more complete list of the sectors than we had before: from biotech to health IT to providers to policy.
In the end, though, this site simply looks better. It’s cleaner, it loads faster, and you’re able to click on and access more information on every page. The new design is a clean, sophisticated and elegant look by my new Breaking Media teammates.
A Deep-dive Into Specialty Pharma
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
We’re not done, though: not by a long shot. There are more adjustments to come and we’ll fix any glitches that may be around in the new site changeover. Plus, we want to hear from you. Send me your feedback or post it in the comments below and we’ll tweak the look and feel based on your thoughts.
MedCity News: 2010
MedCity News: March 2015
MedCity News: May 2015
Photo: Flickr user Eric Heupel
